BridgeBio Pharma Files 8-K Report
Ticker: BBIO · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1743881
| Field | Detail |
|---|---|
| Company | Bridgebio Pharma, Inc. (BBIO) |
| Form Type | 8-K |
| Filed Date | Oct 27, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: BBIO
TL;DR
BridgeBio Pharma filed an 8-K on 10/27/25. Keep an eye out for details.
AI Summary
On October 27, 2025, BridgeBio Pharma, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates BridgeBio Pharma, Inc. is making a regulatory submission to the SEC, which could contain important updates for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain information about specific risks or material events.
Key Players & Entities
- BridgeBio Pharma, Inc. (company) — Registrant
- October 27, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 3160 Porter Dr., Suite 250 (address) — Principal Executive Offices
- Palo Alto, CA 94304 (address) — Principal Executive Offices
- (650) 391-9740 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting "Other Events" and "Financial Statements and Exhibits" as of October 27, 2025.
When was this 8-K report filed?
The report was filed on October 27, 2025.
What is the company's principal executive office address?
The principal executive offices are located at 3160 Porter Dr., Suite 250, Palo Alto, CA 94304.
What is the company's state of incorporation?
BridgeBio Pharma, Inc. is incorporated in Delaware.
Does the filing excerpt mention any specific financial results or material events?
No, the provided excerpt of the 8-K filing does not detail specific financial results or material events; it primarily covers the filing's administrative information and categories.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2025-10-27 16:11:32
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share BBIO The Nasdaq Global Se
Filing Documents
- ef20057750_8k.htm (8-K) — 28KB
- ef20057750_ex99-1.htm (EX-99.1) — 28KB
- 0001140361-25-039463.txt ( ) — 189KB
- bbio-20251027.xsd (EX-101.SCH) — 4KB
- bbio-20251027_lab.xml (EX-101.LAB) — 21KB
- bbio-20251027_pre.xml (EX-101.PRE) — 16KB
- ef20057750_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events On October 27, 2025, BridgeBio Pharma, Inc. issued a press release titled "BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release titled, "BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BridgeBio Pharma, Inc. Date: October 27, 2025 By: /s/ Thomas Trimarchi Thomas Trimarchi, Ph.D. President and Chief Financial Officer